Toggle navigation
Home
Search
Services
Blog
Contact
About
Post Exposure Prophylaxis Against HIV 1 by CD4 IGG2
Maddon, Paul J.
Progenics Pharmaceuticals, Inc., Tarrytown, NY, United States
Search 24 grants from Paul Maddon
Search grants from Progenics Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Role of Metastatic Tumor Antigen-1 in Mammary Gland
Conotoxins and Homeric Nicotinic Acetylcholine Receptors
Improved Techniques for Chest Radiography
Scintigraphy of the Cardiac Adrenergic Nervous System
Surgical Treatment of Cardiac Arrhythmias
Recently added grants:
Resolving differences between clinical opioids at single neurons
Sexual dimorphism, hepatic mitochondrial adaptations, and hepatic steatosis
Credentialing Delta-like 3 (DLL3) as an oncoprotein and immunotherapeutic target in neuroblastoma
Enhancing Physical Activity Adoption and Maintenance in Adults with Obesity by Understanding Motivation for Exercise: A Mixed Methods Research Design
Protein Arginine Methylation in Chemotherapy Resistance
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI036818-02
Application #
2004162
Study Section
Special Emphasis Panel (ZRG5-ARRA (01))
Project Start
1996-09-30
Project End
1998-09-29
Budget Start
1996-09-30
Budget End
1997-09-29
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Progenics Pharmaceuticals, Inc.
Department
Type
DUNS #
945494490
City
Tarrytown
State
NY
Country
United States
Zip Code
10591
Related projects
NIH 1997
R44 AI
Post Exposure Prophylaxis Against HIV 1 by CD4 IGG2
Maddon, Paul J. / Progenics Pharmaceuticals, Inc.
NIH 1996
R44 AI
Post Exposure Prophylaxis Against HIV 1 by CD4 IGG2
Maddon, Paul J. / Progenics Pharmaceuticals, Inc.
Comments
Be the first to comment on Paul Maddon's grant